Ivabradine Mylan

Ivabradine, the active ingredient in Ivabradine Mylan, is a If channel inhibitor presented as an oral tablet for oral use. It is used to manage chronic stable angina and certain forms of heart failure by lowering heart rate without affecting contractility.

GNH USA supplies Ivabradine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to control heart rate in specific cardiovascular conditions.

Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. Heart failure (reduced ejection fraction): improves symptoms and exercise tolerance through heart‑rate reduction.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Bradycardia: slower than normal heart rate. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical attention. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - Persistent visual impairment. - Allergic reactions such as rash or angioedema. - Hepatic enzyme elevations.

Before prescribing Ivabradine, clinicians should assess cardiovascular status and concomitant medications. - Cardiovascular assessment: evaluate heart rate and rhythm. - Concomitant beta‑blockers: avoid excessive heart‑rate lowering. - CYP3A4 inhibitors: adjust dose or avoid use. - Renal or hepatic impairment: monitor for accumulation. - Pregnancy/Breastfeeding: safety not established; use only if benefits outweigh risks. - Store at room temperature: keep in the original pack, protect from moisture.

Ivabradine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Other heart‑rate‑lowering agents (e.g., verapamil, diltiazem): risk of excessive bradycardia. - Concurrent use with other If channel blockers.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may require dose adjustment. - Digoxin: monitor for additive effects on cardiac conduction. - Antihypertensive agents: watch for combined blood‑pressure lowering.